Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential gene expression in murine bone marrow-derived macrophages upon GABA treatment

ABSTRACT: Differential gene expression in murine bone marrow-derived macrophages upon GABA treatment

PROVIDER: PRJNA454829 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7102074_1.fastq.gz	Fastqsanger.gz
	SRR7102074_2.fastq.gz	Fastqsanger.gz
	SRR7102075_1.fastq.gz	Fastqsanger.gz
	SRR7102075_2.fastq.gz	Fastqsanger.gz
	SRR7102076_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Differential gene expression in murine bone marrow-derived macrophages upon GABA treatment

Project description:We investigated the molecular mechanisms by which GABA regulates host defense in macrophages. To examine this, we performed global gene expression analysis of bone marrow-derived macrophages (BMDMs) after GABA treatment.

2018-05-04 | GSE113999 | GEO

GABA produced by multiple bone marrow niche cell types regulate hematopoietic stem and progenitor cells

Project description:Hematopoietic stem and progenitor cells (HSPCs) maintain homeostasis of the blood system by balancing proliferation and differentiation. Many extrinsic signals in the bone marrow (BM) microenvironment that regulate this balance are still unknown. We report gamma aminobutyric acid (GABA) metabolite produced in the BM as a regulator of HSPCs . Deletion of the glutamate decarboxylase enzymes (Gad1/2) that produce GABA in either B lineages or BM endothelial cells (BMECs) leads to a moderate reduction in BM GABA levels and HSPC number, suggesting both cell types are GABA sources. However, simultaneous blockade of GABA production from both hematopoietic cells and BMECs resulted in a greater reduction of both GABA levels and HSPC numbers. Lower GABA levels in the BM altered the gene expression profile of HSPCs, with expression reduced for proliferation-associated genes and increased for B lineage genes . Our findings suggest GABA from multiple sources coordinates to regulate HSPC activity.

2025-10-16 | GSE294951 | GEO

Differential gene expression in M. tuberculosis infected-murine bone marrow-derived macrophages upon colchicine treatment

Project description:Differential gene expression in M. tuberculosis infected-murine bone marrow-derived macrophages upon colchicine treatment

| PRJNA760787 | ENA

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Project description:RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.

| 2004880 | ecrin-mdr-crc

Differential gene expression in M. tuberculosis infected-murine bone marrow-derived macrophages upon colchicine treatment

Project description:We investigated the molecular mechanisms by which colchicine regulates host defense in macrophages against M. tuberculosis infection. To elucidate this, we performed global gene expression analysis of M. tuberculosis infected-bone marrow-derived macrophages after colchicine treatment.

2021-09-11 | GSE183440 | GEO

Bone marrow niche

Project description:Bone marrow niche

| PRJNA429031 | ENA

GABA produced by multiple bone marrow niche cell types regulate hematopoietic stem and progenitor cells

Project description:GABA produced by multiple bone marrow niche cell types regulate hematopoietic stem and progenitor cells

| PRJNA1252090 | ENA

Murine bone marrow derived macrophages: wildtype Vs. CDK5R1 knockout

Project description:Transcriptional profiling of mouse bone marrow derived macrophages comparing wildtype with CDK5R1 knockout. CDK5R1 is an activating parter for CDK5 and synthesized upon TLRs stimaultion. Activated CDK5 has various target substrates, and functions as a key singnaling regulator in macrophages.

2014-11-20 | GSE63443 | GEO

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Project description:This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with high-risk hematologic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells by stopping them from dividing or killing them. Giving cyclophosphamide after transplant may also stop the patient’s immune system from rejecting the donor’s bone marrow stem cells. The donated stem cells may replace the patient’s immune system cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body’s normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening

| 2008483 | ecrin-mdr-crc

bone marrow metagenome

Project description:Rashidi - 7D Bone Marrow

| PRJNA698990 | ENA